Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...

Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...

Revenue: US$40.5m (up 9.9% from FY 2023). Net loss: US$69.2m (loss narrowed by 60% from FY 2023). US$0.56 loss per share (improved from US$1.48 loss in FY 2023). Revenue exceeded analyst estimates ...

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com.

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.

Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...

March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...

March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ ... to reduced costs associated with manufacturing and clinical development activities for UpRi, reduced employee compensation ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Mersana Therapeutics, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has received a notification from The Nasdaq Stock Market LLC regarding non-compliance with the exchange's ...